Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PBRM1 loss |
| Therapy | unspecified CTLA4 antibody + unspecified PD-1 antibody |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PBRM1 loss | melanoma | sensitive | unspecified CTLA4 antibody + unspecified PD-1 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, knocking-out PBRM1 in melanoma cells sensitized cells to immune therapy consisted of anti-CTLA4 and anti-PD-1 antibodies in culture and in cell line xenograft models, potentially due to increased sensitivity to T cell-mediated cytotoxicity and a favorable tumor microenvironment (PMID: 29301958). | 29301958 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29301958) | A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. | Full reference... |